Deltarasin

The KRAS oncogene product is considered a major target in anticancer drug discovery. Interfering with binding of mammalian PDE? to KRAS by means of small molecules provides a novel opportunity to suppress oncogenic RAS signalling by altering its localization to endomembranes.